ACT News 223.05 07/01/2014 04:22:57 Actavis Inc (ACT)
Post# of 273330
Posted On: 07/01/2014 5:22:52 AM
Actavis Inc (ACT) 223.05 $ACT
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest
Business Wire - Mon Jun 30, 4:15PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest's agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtaining FTC approval. The closing of the transaction remains subject to other customary closing conditions, and is expected to be effective on July 1, 2014.
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
Business Wire - Mon Jun 30, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis' pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on July 1st, 2014.
Actavis to Host Second Quarter 2014 Earnings Conference Call and Webcast
PR Newswire - Mon Jun 30, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release second quarter 2014 financial results on Tuesday, August 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 65351447.
Actavis Confirms Generic Zubsolv® Patent Challenge
PR Newswire - Mon Jun 30, 6:30AM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv®, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Many IBD 50 Stocks Struggle To Climb After Breakouts
at Investor's Business Daily - Fri Jun 27, 6:08PM CDT
A number of IBD 50 stocks have cleared buy points recently, but many of them have made little progress. Noneof the stocks is flashing a sell signal, but many of the bases are riskier late-stage patterns. As a result, investors should remain vigilant,...
Auxilium and QLT to Merge on Tax Saving Attractions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 11:10AM CDT
Auxilium (AUXL) and QLT (QLTI) will combine by year end.
Novo, Other Medicals Display Healthy Action
at Investor's Business Daily - Thu Jun 26, 5:41PM CDT
Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs. But a raft of medical plays in today's Your Weekly Review are showing fairly healthy action as they work on bases or move near buy...
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.
World Market for Pain Management Drugs and Devices to 2017
M2 - Thu Jun 26, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xbzv4k/the_world_market) has announced the addition of the "The World Market for Pain Management Drugs and Devices" report to their offering. The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain management will likely involve multidisciplinary departments dedicated to finding treatments that manage pain. The need is great worldwide for management of pain and there are still many facets of pain management that need to be explored. Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain. The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management. The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories: - Burn Pain - Cancer Pain - Dental/Facial Pain - Migraine Headache Pain - Musculoskeletal Pain - Neuropathic Pain - Obstetrical Pain - Pediatric Pain - Surgical and Trauma Pain This report details the various categories of top prescription pain management drugs, describes U.S., European, Japanese and other markets in each of the specific pain areas. The report also covers drug delivery methods, pain management devices, and alternate treatment modalities that are influencing the market. It further identifies major market factors, which are discussed, and a total market summary is presented. As part of the study the following competitors are profiled: - Abbott Laboratories - Actavis, Inc (formerly Watson Pharmaceuticals, Inc.) - AstraZeneca plc. - Baxter International, Inc. - BioDelivery Sciences International (BDSI) - Boehringer Ingelheim - Boston Scientific - Bristol-Myers Squibb Company - DepoMed - DURECT Corporation - Eli Lilly & Co. - Endo Health Solutions Inc - GlaxoSmithKline plc - Grunenthal Group - Medtronic, Inc. - Merck & Co. - Novartis - Pain Therapeutics, Inc - Pfizer, Inc - Purdue Pharma - QRx Pharma - Sanofi - St. Jude Medical, Inc - TEVA Pharmaceuticals Industries, Ltd - The Medicines Company - Valeant Pharmaceuticals International, Inc. - Zogenix, Inc. For more information visit http://www.researchandmarkets.com/research/xb...rld_market
Endo International to Expand Generics Business with DAVA Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 2:20PM CDT
Endo (ENDP) has inked a deal to buy DAVA Pharmaceuticals for a cash consideration of approximately $575 million.
Love the Stocks Everyone Hates: 5 Short-Squeeze Stocks Ready to Pop
at The Street - Wed Jun 25, 9:34AM CDT
These heavily shorted stocks could get squeezed on any positive catalyst.
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.
Are Investors Wrong About VIVUS?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Whenever short-sellers start jumping into a stock with both feet, it's generally a good idea to understand why. VIVUS has seen its short interest skyrocket this year to over 35% of the float, while the company's share price has subsequently...
Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline"
. The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1, 2014. Forest stockholders who hold shares through a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee.
Major Indexes Narrowly Lower As Actavis Rallies
at Investor's Business Daily - Mon Jun 23, 12:29PM CDT
Despite better-than-expected economic data, the major averages were still trading flat to slightly lower in early-afternoon trading. The Nasdaq was flat, while the S&P 500 edged down 0.1% and the Dow industrials eased 0.2%. Volume was tracking well...
3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest
Business Wire - Mon Jun 30, 4:15PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest's agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtaining FTC approval. The closing of the transaction remains subject to other customary closing conditions, and is expected to be effective on July 1, 2014.
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
Business Wire - Mon Jun 30, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis' pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on July 1st, 2014.
Actavis to Host Second Quarter 2014 Earnings Conference Call and Webcast
PR Newswire - Mon Jun 30, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release second quarter 2014 financial results on Tuesday, August 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 65351447.
Actavis Confirms Generic Zubsolv® Patent Challenge
PR Newswire - Mon Jun 30, 6:30AM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv®, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Many IBD 50 Stocks Struggle To Climb After Breakouts
at Investor's Business Daily - Fri Jun 27, 6:08PM CDT
A number of IBD 50 stocks have cleared buy points recently, but many of them have made little progress. Noneof the stocks is flashing a sell signal, but many of the bases are riskier late-stage patterns. As a result, investors should remain vigilant,...
Auxilium and QLT to Merge on Tax Saving Attractions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 11:10AM CDT
Auxilium (AUXL) and QLT (QLTI) will combine by year end.
Novo, Other Medicals Display Healthy Action
at Investor's Business Daily - Thu Jun 26, 5:41PM CDT
Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs. But a raft of medical plays in today's Your Weekly Review are showing fairly healthy action as they work on bases or move near buy...
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.
World Market for Pain Management Drugs and Devices to 2017
M2 - Thu Jun 26, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xbzv4k/the_world_market) has announced the addition of the "The World Market for Pain Management Drugs and Devices" report to their offering. The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain management will likely involve multidisciplinary departments dedicated to finding treatments that manage pain. The need is great worldwide for management of pain and there are still many facets of pain management that need to be explored. Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain. The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management. The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories: - Burn Pain - Cancer Pain - Dental/Facial Pain - Migraine Headache Pain - Musculoskeletal Pain - Neuropathic Pain - Obstetrical Pain - Pediatric Pain - Surgical and Trauma Pain This report details the various categories of top prescription pain management drugs, describes U.S., European, Japanese and other markets in each of the specific pain areas. The report also covers drug delivery methods, pain management devices, and alternate treatment modalities that are influencing the market. It further identifies major market factors, which are discussed, and a total market summary is presented. As part of the study the following competitors are profiled: - Abbott Laboratories - Actavis, Inc (formerly Watson Pharmaceuticals, Inc.) - AstraZeneca plc. - Baxter International, Inc. - BioDelivery Sciences International (BDSI) - Boehringer Ingelheim - Boston Scientific - Bristol-Myers Squibb Company - DepoMed - DURECT Corporation - Eli Lilly & Co. - Endo Health Solutions Inc - GlaxoSmithKline plc - Grunenthal Group - Medtronic, Inc. - Merck & Co. - Novartis - Pain Therapeutics, Inc - Pfizer, Inc - Purdue Pharma - QRx Pharma - Sanofi - St. Jude Medical, Inc - TEVA Pharmaceuticals Industries, Ltd - The Medicines Company - Valeant Pharmaceuticals International, Inc. - Zogenix, Inc. For more information visit http://www.researchandmarkets.com/research/xb...rld_market
Endo International to Expand Generics Business with DAVA Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 2:20PM CDT
Endo (ENDP) has inked a deal to buy DAVA Pharmaceuticals for a cash consideration of approximately $575 million.
Love the Stocks Everyone Hates: 5 Short-Squeeze Stocks Ready to Pop
at The Street - Wed Jun 25, 9:34AM CDT
These heavily shorted stocks could get squeezed on any positive catalyst.
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.
Are Investors Wrong About VIVUS?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Whenever short-sellers start jumping into a stock with both feet, it's generally a good idea to understand why. VIVUS has seen its short interest skyrocket this year to over 35% of the float, while the company's share price has subsequently...
Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline"
. The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1, 2014. Forest stockholders who hold shares through a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee. Major Indexes Narrowly Lower As Actavis Rallies
at Investor's Business Daily - Mon Jun 23, 12:29PM CDT
Despite better-than-expected economic data, the major averages were still trading flat to slightly lower in early-afternoon trading. The Nasdaq was flat, while the S&P 500 edged down 0.1% and the Dow industrials eased 0.2%. Volume was tracking well...
3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
(0)
(0)